JP2019533651A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533651A5
JP2019533651A5 JP2019517236A JP2019517236A JP2019533651A5 JP 2019533651 A5 JP2019533651 A5 JP 2019533651A5 JP 2019517236 A JP2019517236 A JP 2019517236A JP 2019517236 A JP2019517236 A JP 2019517236A JP 2019533651 A5 JP2019533651 A5 JP 2019533651A5
Authority
JP
Japan
Prior art keywords
cancer
subject
administering
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019517236A
Other languages
English (en)
Japanese (ja)
Other versions
JP6801093B2 (ja
JP2019533651A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/055660 external-priority patent/WO2018068021A1/en
Publication of JP2019533651A publication Critical patent/JP2019533651A/ja
Publication of JP2019533651A5 publication Critical patent/JP2019533651A5/ja
Application granted granted Critical
Publication of JP6801093B2 publication Critical patent/JP6801093B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019517236A 2016-10-07 2017-10-06 グルココルチコイド受容体の阻害剤 Active JP6801093B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US62/405,801 2016-10-07
US201762526331P 2017-06-28 2017-06-28
US62/526,331 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020191820A Division JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Publications (3)

Publication Number Publication Date
JP2019533651A JP2019533651A (ja) 2019-11-21
JP2019533651A5 true JP2019533651A5 (enExample) 2020-08-06
JP6801093B2 JP6801093B2 (ja) 2020-12-16

Family

ID=61832215

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019517236A Active JP6801093B2 (ja) 2016-10-07 2017-10-06 グルココルチコイド受容体の阻害剤
JP2020191820A Ceased JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020191820A Ceased JP2021046409A (ja) 2016-10-07 2020-11-18 グルココルチコイド受容体の阻害剤

Country Status (20)

Country Link
US (5) US10472387B2 (enExample)
EP (2) EP3851444A1 (enExample)
JP (2) JP6801093B2 (enExample)
KR (2) KR102237916B1 (enExample)
CN (2) CN111690031B (enExample)
AU (3) AU2017339510B2 (enExample)
BR (1) BR112019006987B1 (enExample)
CA (1) CA3039636C (enExample)
DK (1) DK3523315T3 (enExample)
ES (1) ES2867853T3 (enExample)
HU (1) HUE054542T2 (enExample)
IL (2) IL265835B (enExample)
MX (2) MX385658B (enExample)
NZ (1) NZ753142A (enExample)
PL (1) PL3523315T3 (enExample)
PT (1) PT3523315T (enExample)
SG (1) SG11201903055UA (enExample)
SI (1) SI3523315T1 (enExample)
WO (1) WO2018068021A1 (enExample)
ZA (1) ZA202004440B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394078A4 (en) 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
KR20210000719A (ko) * 2018-04-11 2021-01-05 오릭 파마슈티칼스, 인크. 글루코코르티코이드 수용체 길항제를 포함하는 고체 형태 및 제제 및 그의 용도
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
WO2021226465A1 (en) * 2020-05-08 2021-11-11 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
BE1004905A4 (fr) 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
DE69413829T2 (de) 1993-08-04 1999-04-15 Akzo Nobel N.V., Arnheim/Arnhem Antiglucocorticoidsteroide zur behandlung von angststörungen
WO1995017192A1 (en) 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
CA2186953C (en) 1995-02-02 2009-11-10 Kristof Chwalsz Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
PT1989218E (pt) 2006-02-17 2010-02-01 Janssen Pharmactuica N V Derivados de 17-fósforo esteróides úteis como moduladores do receptor da progesterona
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2148681B1 (en) 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013126581A1 (en) 2012-02-24 2013-08-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CA2933590C (en) * 2013-12-11 2023-10-03 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
EP3394078A4 (en) * 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6995757B2 (ja) * 2015-12-23 2022-01-17 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
WO2018227129A1 (en) 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
KR20210000719A (ko) 2018-04-11 2021-01-05 오릭 파마슈티칼스, 인크. 글루코코르티코이드 수용체 길항제를 포함하는 고체 형태 및 제제 및 그의 용도

Similar Documents

Publication Publication Date Title
JP2019533651A5 (enExample)
JP2019501204A5 (enExample)
EP4219563A3 (en) Methods of treating cancer with anti-pd-1 antibodies
JP2017516775A5 (enExample)
JP2013520442A5 (enExample)
JP2019516711A5 (enExample)
JP2018508512A5 (enExample)
JP2016501221A5 (enExample)
JP2015534577A5 (enExample)
JP2015534578A5 (enExample)
JP2015500225A5 (enExample)
JP2016514689A5 (enExample)
JP2015534580A5 (enExample)
JP2016502504A5 (enExample)
JP2016528246A5 (enExample)
MX2016008362A (es) Combinaciones farmaceuticas.
JP2012153722A5 (enExample)
JP2015534579A5 (enExample)
JP2018504418A5 (enExample)
JP2007526455A5 (enExample)
JP2013522326A5 (enExample)
JP2019532047A5 (enExample)
JP2017518291A5 (enExample)
JP2016513696A5 (enExample)
JP2016503414A5 (enExample)